Annual EBITDA
-$252.55 M
-$26.69 M-11.82%
December 31, 2023
Summary
- As of February 7, 2025, ZNTL annual EBITDA is -$252.55 million, with the most recent change of -$26.69 million (-11.82%) on December 31, 2023.
- During the last 3 years, ZNTL annual EBITDA has fallen by -$133.93 million (-112.90%).
- ZNTL annual EBITDA is now -964.18% below its all-time high of -$23.73 million, reached on December 31, 2018.
Performance
ZNTL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$51.11 M
+$13.71 M+21.15%
September 30, 2024
Summary
- As of February 7, 2025, ZNTL quarterly EBITDA is -$51.11 million, with the most recent change of +$13.71 million (+21.15%) on September 30, 2024.
- Over the past year, ZNTL quarterly EBITDA has increased by +$11.26 million (+18.05%).
- ZNTL quarterly EBITDA is now -487.42% below its all-time high of -$8.70 million, reached on March 31, 2019.
Performance
ZNTL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$207.96 M
+$11.26 M+5.14%
September 30, 2024
Summary
- As of February 7, 2025, ZNTL TTM EBITDA is -$207.96 million, with the most recent change of +$11.26 million (+5.14%) on September 30, 2024.
- Over the past year, ZNTL TTM EBITDA has increased by +$28.40 million (+12.02%).
- ZNTL TTM EBITDA is now -2290.05% below its all-time high of -$8.70 million, reached on March 31, 2019.
Performance
ZNTL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ZNTL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -11.8% | +18.1% | +12.0% |
| 3 y3 years | -112.9% | +18.1% | +12.0% |
| 5 y5 years | -964.2% | +18.1% | +12.0% |
ZNTL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.9% | at low | -109.1% | +24.4% | at high | +17.7% |
| 5 y | 5-year | -440.4% | at low | -243.9% | +24.4% | -345.0% | +17.7% |
| alltime | all time | -964.2% | at low | -487.4% | +24.4% | -2290.1% | +17.7% |
Zentalis Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$51.11 M(-21.2%) | -$207.96 M(-5.1%) |
| Jun 2024 | - | -$64.82 M(+165.2%) | -$219.22 M(+3.2%) |
| Mar 2024 | - | -$24.44 M(-63.8%) | -$212.40 M(-15.9%) |
| Dec 2023 | -$252.55 M(+11.8%) | -$67.58 M(+8.4%) | -$252.55 M(+6.8%) |
| Sep 2023 | - | -$62.37 M(+7.5%) | -$236.36 M(+3.8%) |
| Jun 2023 | - | -$58.00 M(-10.2%) | -$227.81 M(-2.2%) |
| Mar 2023 | - | -$64.59 M(+25.7%) | -$232.92 M(+3.1%) |
| Dec 2022 | -$225.86 M(+4.6%) | -$51.40 M(-4.5%) | -$225.86 M(+1.5%) |
| Sep 2022 | - | -$53.82 M(-14.7%) | -$222.45 M(-3.9%) |
| Jun 2022 | - | -$63.11 M(+9.7%) | -$231.37 M(+3.6%) |
| Mar 2022 | - | -$57.53 M(+19.9%) | -$223.26 M(+3.4%) |
| Dec 2021 | -$216.00 M | -$47.98 M(-23.5%) | -$216.00 M(+3.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$62.73 M(+14.0%) | -$208.23 M(+15.5%) |
| Jun 2021 | - | -$55.01 M(+9.4%) | -$180.21 M(+18.1%) |
| Mar 2021 | - | -$50.27 M(+25.0%) | -$152.53 M(+28.6%) |
| Dec 2020 | -$118.63 M(+153.8%) | -$40.21 M(+15.8%) | -$118.63 M(+27.2%) |
| Sep 2020 | - | -$34.72 M(+27.0%) | -$93.28 M(+31.2%) |
| Jun 2020 | - | -$27.34 M(+67.1%) | -$71.12 M(+30.8%) |
| Mar 2020 | - | -$16.36 M(+10.1%) | -$54.39 M(+16.4%) |
| Dec 2019 | -$46.73 M(+96.9%) | -$14.86 M(+18.4%) | -$46.73 M(+46.6%) |
| Sep 2019 | - | -$12.56 M(+18.3%) | -$31.87 M(+65.0%) |
| Jun 2019 | - | -$10.61 M(+22.0%) | -$19.31 M(+122.0%) |
| Mar 2019 | - | -$8.70 M | -$8.70 M |
| Dec 2018 | -$23.73 M | - | - |
FAQ
- What is Zentalis Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Zentalis Pharmaceuticals?
- What is Zentalis Pharmaceuticals annual EBITDA year-on-year change?
- What is Zentalis Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Zentalis Pharmaceuticals?
- What is Zentalis Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Zentalis Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Zentalis Pharmaceuticals?
- What is Zentalis Pharmaceuticals TTM EBITDA year-on-year change?
What is Zentalis Pharmaceuticals annual EBITDA?
The current annual EBITDA of ZNTL is -$252.55 M
What is the all time high annual EBITDA for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals all-time high annual EBITDA is -$23.73 M
What is Zentalis Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ZNTL annual EBITDA has changed by -$26.69 M (-11.82%)
What is Zentalis Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of ZNTL is -$51.11 M
What is the all time high quarterly EBITDA for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals all-time high quarterly EBITDA is -$8.70 M
What is Zentalis Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ZNTL quarterly EBITDA has changed by +$11.26 M (+18.05%)
What is Zentalis Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of ZNTL is -$207.96 M
What is the all time high TTM EBITDA for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals all-time high TTM EBITDA is -$8.70 M
What is Zentalis Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ZNTL TTM EBITDA has changed by +$28.40 M (+12.02%)